TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
TScan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.21−0.02 (-9.00%)
Close on Oct 19, 2026
- Market cap
- $27.32M
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$10.33MFY2025, +56.9% a year since FY2020